What is the main difference between Opicapone and Cordan?

Opicapone and Entacapone (Entacapone tablets, Entacapone) both belong to the catechol-O-methyltransferase (COMT) inhibitor class of drugs. They are mainly used for the adjuvant treatment of Parkinson's disease (PD) to improve the fluctuation of the efficacy of Levodopa and reduce the "wearing-off" phenomenon. Although their mechanisms of action are similar, there are significant differences between the two in terms of drug structure, duration of action, dosage requirements, and adverse reactions.

First of all, in terms of pharmacokinetics, opicapone is a long-acting COMT inhibitor with a half-life of about 100 hours and only needs to be taken once a day, while entacapone has a shorter half-life, usually only 1-2 hours. Therefore, patients need to take it in combination with levodopa/carbidopa (L-Dopa/Carbidopa), and entacapone needs to be taken more frequently every time they take the drug. This gives Opicapone significant advantages in reducing the number of medication doses and improving patient compliance.

Secondly, in terms of efficacy, research shows that compared with entacapone, Opicapone is more effective in prolonging the "ON-time" and reducing the "OFF-time", that is, Parkinson's patients can maintain better motor function for a longer period of time throughout the day. In addition, Opicapone is more selective in inhibiting the activity of COMT enzyme and is less likely to affect other peripheral physiological functions, so it has better overall tolerance.

In terms of safety and side effects, Opicapone is relatively better tolerated. The main side effects include dyskinesia, insomnia and gastrointestinal discomfort, while Entacapone may be more likely to cause diarrhea, nausea, urine discoloration, etc. In addition, coadministration of entacapone with levodopa may increase the risk of hypotension and psychiatric symptoms, whereas opicapone is associated with less severe side effects.

To sum up, because of its long-acting characteristics, ease of administration and good tolerability, Opicapone is considered a better choice in the adjuvant treatment of Parkinson's disease, especially for patients who need to reduce the frequency of medication. However, the specific choice of drug still needs to be based on the patient's individual situation and decided by the doctor after evaluation.

Reference materials:https://www.ongentys.com/